Maze Therapeutics Files S-1 for Public Offering

TL;DR

Maze Therapeutics just filed its S-1, looks like they're gearing up for an IPO.

AI Summary

Maze Therapeutics, Inc., incorporated in Delaware, filed an S-1 registration statement on January 7, 2025. The company, located at 171 Oyster Point Boulevard, Suite 300, South San Francisco, California, is in the biological products sector. The filing indicates a public offering is being prepared, with Jason Coloma, Ph.D., serving as Chief Executive Officer.

Why It Matters

This S-1 filing signals Maze Therapeutics' intention to go public, which could provide significant capital for its research and development in the biological products sector.

Risk Assessment

Risk Level: medium — As a pre-IPO company in the biotech sector, Maze Therapeutics faces inherent risks related to clinical trials, regulatory approval, and market adoption.

Key Numbers

• 333-284164 — SEC File Number (Identifies this specific registration statement)
• 25515056 — Film Number (Internal SEC processing number)

Key Players & Entities

• Maze Therapeutics, Inc. (company) — Registrant
• January 7, 2025 (date) — Filing Date
• 171 Oyster Point Boulevard, Suite 300 (address) — Principal Executive Offices
• South San Francisco, California (address) — Principal Executive Offices Location
• Jason Coloma, Ph.D. (person) — Chief Executive Officer
• Delaware (jurisdiction) — State of Incorporation
• 2836 (sic_code) — Standard Industrial Classification

FAQ

Key Financial Figures

• $150 million — 1 to Shionogi for an upfront payment of $150 million and the potential for additional milest

Filing Documents

• d769642ds1.htm (S-1) — 2210KB
• d769642dex31.htm (EX-3.1) — 118KB
• d769642dex32.htm (EX-3.2) — 32KB
• d769642dex33.htm (EX-3.3) — 70KB
• d769642dex34.htm (EX-3.4) — 173KB
• d769642dex42.htm (EX-4.2) — 246KB
• d769642dex101.htm (EX-10.1) — 60KB
• d769642dex102.htm (EX-10.2) — 300KB
• d769642dex103.htm (EX-10.3) — 355KB
• d769642dex104.htm (EX-10.4) — 366KB
• d769642dex105.htm (EX-10.5) — 115KB
• d769642dex106.htm (EX-10.6) — 479KB
• d769642dex107.htm (EX-10.7) — 38KB
• d769642dex108.htm (EX-10.8) — 48KB
• d769642dex109.htm (EX-10.9) — 175KB
• d769642dex1010.htm (EX-10.10) — 346KB
• d769642dex1011.htm (EX-10.11) — 15KB
• d769642dex1014.htm (EX-10.14) — 13KB
• d769642dex1015.htm (EX-10.15) — 65KB
• d769642dex231.htm (EX-23.1) — 1KB
• d769642dex991.htm (EX-99.1) — 3KB
• d769642dexfilingfees.htm (EX-FILING FEES) — 13KB
• g769642g01a13.jpg (GRAPHIC) — 133KB
• g769642g02g02.jpg (GRAPHIC) — 212KB
• g769642g05f43.jpg (GRAPHIC) — 588KB
• g769642g1224171233822.jpg (GRAPHIC) — 1KB
• g769642g13a01.jpg (GRAPHIC) — 154KB
• g769642g30x67.jpg (GRAPHIC) — 35KB
• g769642g31l38.jpg (GRAPHIC) — 114KB
• g769642g55f74.jpg (GRAPHIC) — 57KB
• g769642g62f25.jpg (GRAPHIC) — 63KB
• g769642g66t55.jpg (GRAPHIC) — 32KB
• g769642g72h13.jpg (GRAPHIC) — 35KB
• g769642g72u41.jpg (GRAPHIC) — 28KB
• g769642g74a05.jpg (GRAPHIC) — 120KB
• g769642g76l04.jpg (GRAPHIC) — 54KB
• g769642g77q77.jpg (GRAPHIC) — 33KB
• g769642g81q05.jpg (GRAPHIC) — 39KB
• g769642g94f07.jpg (GRAPHIC) — 108KB
• g769642g96l94.jpg (GRAPHIC) — 66KB
• g769642g98g45.jpg (GRAPHIC) — 42KB
• g769642g98o36.jpg (GRAPHIC) — 31KB
• 0001193125-25-002851.txt ( ) — 7894KB

Risk factors

Risk factors 15 Special note regarding forward-looking statements 82

Use of proceeds

Use of proceeds 85 Dividend policy 87 Capitalization 88

Managements discussion and analysis of financial condition and results of operations

Managements discussion and analysis of financial condition and results of operations 94

Business

Business 114 Management 160

Executive compensation

Executive compensation 173 Certain relationships and related party transactions 188 Principal stockholders 192

Description of capital stock

Description of capital stock 195 Shares eligible for future sale 201 Material U.S. federal income tax consequences to non-U.S. holders 203

Underwriting

Underwriting 208 Legal matters 220 Experts 220 Where you can find additional information 220 Index to financial statements F-1 Through and including, 2025 (the 25th day after the date of this prospectus), all dealers effecting transactions in these securities, whether or not participating in this offering, may be required to deliver a prospectus. This delivery requirement is in addition to a dealers obligation to deliver a prospectus when acting as an underwriter and with respect to an unsold allotment or subscription . Neither we nor the underwriters have authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectuses we have prepared. We and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the shares offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus or in any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or the time of any sale of shares of our common stock. i Table of Contents For investors outside of the United States: Neither we nor any of the underwriters have done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than the United States. Persons outside of the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of our common stock and the distribution of this prospectus outside of the United States. ii Table of Contents Prospectus summary This summary highlights selected information contained elsewhere in this prospectus and does not contain

View Full Filing

View this S-1 filing on SEC EDGAR